Avalo Therapeutics to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avalo Therapeutics (Nasdaq: AVTX) said its management will present at two investor conferences in February 2026: a Guggenheim Emerging Outlook Biotech Summit fireside chat on February 11, 2026 at 10:00 AM ET and an Oppenheimer Healthcare Life Sciences fireside chat on February 25, 2026 at 10:00 AM ET.
Live webcasts and replays will be posted under News / Events on the Avalo Therapeutics investor website, with archived webcasts available for at least 30 days.
Details
News Market Reaction – AVTX
On Feb 4, the day this news came out, AVTX closed 9.96% below the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:
Guggenheim Emerging Outlook: Biotech Summit 2026
Fireside Chat
February 11, 2026, at 10:00 am ET
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Fireside Chat
February 25, 2026, at 10:00 am ET
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.1 It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune-mediated inflammatory diseases.1-3
References:1Dinarello CA. Immunol Rev. 2018;281(1):8-27. 2Kany S et al. Int J Mol Sci. 2019;20(23):6008. 3Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.